RADIOTHERAPY PSA nadir predicts long-term mortality

被引：6
作者：
Buyyounouski, Mark K. [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2010年 / 7卷 / 04期
关键词：
PROSTATE-SPECIFIC ANTIGEN; BEAM RADIATION-THERAPY; BIOCHEMICAL FAILURE; CANCER; METASTASIS; SURVIVAL; INTERVAL;
D O I：
10.1038/nrclinonc.2010.33
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The effect of PSA level on distant metastases and cause-specific mortality was assessed in a recent study, and showed a nadir PSA level 1.5 ng/ml within 2 years of radiotherapy treatment predicts distant metastases and death from prostate cancer.
引用
收藏
页码：188 / 190
页数：4
相关论文
共 10 条
  • [1] Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death
    Alcantara, Pino
    Hanlon, Alexandra
    Buyyounouski, Mark K.
    Horwitz, Eric M.
    Pollack, Alan
    [J]. CANCER, 2007, 109 (01) : 41 - 47
  • [2] [Anonymous], 2010, NCCN Clinical Practice Guidelines in Oncology
  • [3] Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer
    Buyyounouski, M. K.
    Pickles, T.
    Kestin, L.
    Allison, R.
    Williams, S. G.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S103 - S104
  • [4] Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy
    Buyyounouski, Mark K.
    Hanlon, Alexandra L.
    Horwitz, Eric M.
    Pollack, Alan
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 70 (01): : 59 - 66
  • [5] Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation
    Buyyounouski, MK
    Hanlon, AL
    Horwitz, EM
    Uzzo, RG
    Pollack, A
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (05): : 1291 - 1298
  • [6] Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy
    Cavanaugh, SX
    Fuller, CD
    Kupelian, PA
    Reddy, C
    Bradshaw, P
    Pollock, BH
    Fuss, M
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2005, 8 (04) : 353 - 358
  • [7] Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease-free survival
    Lee, WR
    Hanlon, AL
    Hanks, GE
    [J]. JOURNAL OF UROLOGY, 1996, 156 (02) : 450 - 453
  • [8] Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure
    Ray, Michael E.
    Levy, Larry B.
    Horwitz, Eric M.
    Kupelian, Patrick A.
    Martinez, Alvaro A.
    Michalski, Jeff M.
    Pisansky, Thomas M.
    Zelefsky, Michael J.
    Zietman, Anthony L.
    Kuban, Deborah A.
    [J]. UROLOGY, 2006, 68 (06) : 1257 - 1262
  • [9] POSTRADIOTHERAPY 2-YEAR PROSTATE-SPECIFIC ANTIGEN NADIR AS A PREDICTOR OF LONG-TERM PROSTATE CANCER MORTALITY
    Zelefsky, Michael J.
    Shi, Weiji
    Yamada, Yoshiya
    Kollmeier, Marisa A.
    Cox, Brett
    Park, Jessica
    Seshan, Venkatraman E.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (05): : 1350 - 1356
  • [10] Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate
    Zietman, AL
    Tibbs, MK
    Dallow, KC
    Smith, CT
    Althausen, AF
    Zlotecki, RA
    Shipley, WU
    [J]. RADIOTHERAPY AND ONCOLOGY, 1996, 40 (02) : 159 - 162
1